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Education and debate
Controversies in management
Should methionine be added to every paracetamol tablet?
No: The risks are not well enough known
A L Jones, P C Hayes, A T Proudfoot, J A Vale, L F Prescott
Each year in the United Kingdom roughly 2600
million tablets of paracetamol are sold over the
counter and 600 million supplied on prescription
(Paracetamol Information Centre Study, November
1993). Paracetamol overdose is common in many parts
of the world.
In studies in Britain and America paracetamol was
the commonest drug used in overdose, being taken in
about 48% of overdoses in Oxford1 and 5% in
America.2 Clinicians in general, and those working in
liver transplant units in particular, are increasingly
aware of the problems raised by the liver damage
caused by paracetamol, and pressure is growing to find
some preventive measure. Adding the antidote
methionine3 to paracetamol tablets is attractive, but
because most people who take overdoses act
impulsively it would have to be added to every formu-
lation to be of maximum value. The critical issue then
is whether the vast numbers of responsible users of
paracetamol should have no choice but to take it with
methionine in order to protect the minority who take
overdoses.
Cost of paracetamol poisoning
Overdose of paracetamol causes hepatotoxicity
ranging from mild, asymptomatic derangement of liver
function to fulminant hepatic failure and death.
Official statistics considerably overestimate the number
of deaths from paracetamol poisoning.4 Thus in 1990,
of 547 deaths attributed to paracetamol in England
and Wales, only 150 were substantiated after review.5
The official returns include people who never reach
hospital and who are more likely to have died from the
effects of other drugs ingested concomitantly
(especially dextropropoxyphene).4 Few conscious
people would suffer the symptoms of severe hepatic
injury for even a few days without seeking medical
attention.
Of 667 patients who received a liver transplant in
the United Kingdom in 1995, only 29 had liver failure
caused by paracetamol poisoning (R Bates, Scottish
Liver Transplant Unit, personal communication). Such
patients are commonly young and the need for
transplantation is invariably urgent. They therefore
receive top priority for donor organs and reduce those
available to other patients.
At any one time, around 100 patients are waiting
for elective liver transplantation in Britain, and as the
average survival time for advanced cirrhosis is less than
one year, some will die while waiting. In the United
States admissions to hospital and days off sick related
to paracetamol overdosage have been estimated to cost
$86.9 million/year.6
The cost of paracetamol poisoning is therefore
high but must be considered in the context of the
drug’s therapeutic benefits, the enormous quantity
sold, and the advantages of its availability over the
counter.
Would a paracetamol and methionine
formulation prevent liver damage?
There have been no reports of overdose with paraceta-
mol and methionine combinations in humans and
therefore no hard evidence exists that liver damage
would be prevented. Nevertheless, adding methionine
to paracetamol tablets to prevent hepatic damage from
overdose has a sound biochemical rationale.
Excessive production of N-acetyl-p-benzo-
quinoneimine, a toxic metabolite of paracetamol,
depletes hepatic glutathione concentrations leading to
covalent binding and destruction of hepatic cells.
Methionine protected against such damage in animal
studies7 8 and in clinical trials (when given to patients
who admitted taking a paracetamol overdose).9-12 It
probably acts by promoting synthesis of glutathione.
The period between taking the overdose and
administration of the methionine is critical since the
hepatocytes must be intact in order to convert the
methionine to cysteine for the synthesis of glutathione.
In clinical practice it prevented significant liver damage
Paracetamol is commonly used for self poisoning, and the costs of treating the resulting liver failure in the
few who develop it are high. The morbidity could be avoided by adding methionine to paracetamol
tablets, but this would mean that the millions of people who take paracetamol responsibly would have to














































301BMJ VOLUME 315 2 AUGUST 1997




Only one paracetamol and methionine combination
preparation remains available in the United Kingdom:
Paradote (500 mg paracetamol, 100 mg methionine).
Pameton (500 mg paracetamol, 250 mg methionine)
has been voluntarily removed from the market because
of safety concerns. Similar preparations are not
currently available in the rest of Europe or in the
United States. Both cost four to six times more than
proprietary paracetamol, and one tastes unpleasant.
Although methionine has few side effects, it causes
nausea and headache in some cases.11 The methionine
in both formulations is the dl racemate, but it is
unlikely that the d form can be converted to the l form
in vivo.13 14
No data are available on the relative efficacy of the
two forms of methionine in protecting the liver after
paracetamol overdose in humans, but if only
l-methionine is bioavailable it would be better to use
this than a racemic mixture. d-Methionine prevented
acute paracetamol hepatotoxicity in rats, but unlike
humans, rats use d-methionine efficiently.15 16
The issue of dose
Another issue is the dose of methionine. As weight
ratios of methionine to paracetamol of as low as 10%
protected rats from hepatotoxicity,7 the ratios used in
Paradote (20%) and particularly the former Pameton
(50%) may be overgenerous. The effective prophylactic
antidotal dose of methionine in humans remains to be
established. The safety of long term ingestion of
methionine in addition to that already in the diet is
important.
Studies of dietary supplementation in healthy peo-
ple have shown reduced serum folate concentrations
and leucocytosis after 8 g of methionine daily for four
days17 and changes in serum pH and potassium with
increased urinary calcium excretion after 13.9 g daily
for five days.18 Schizophrenic patients given 10-20 g
daily for two weeks developed functional psychoses19
and single doses of 8 g precipitated hepatic encepha-
lopathy in patients with cirrhosis.20
Methionine metabolites are involved in the
transformation of malignant cells.21 In addition, in vitro
and in vivo studies in animals with tumours have
shown that restriction of methionine intake specifically
blocks division and metastasis of tumour cells.22 23 The
possibility that long term increased intake of
methionine could promote carcinogenesis has not
been evaluated.
Methionine is metabolised to homocysteine and
vice versa in a methylation cycle, and raised plasma
homocysteine concentrations have been associated
with peripheral vascular disease, ischaemic heart
disease, and stroke24-27; coagulation abnormalities28;
vascular injury29; endothelial dysfunction30; and vascu-
lar smooth muscle proliferation.31 Oral administration
of methionine (200 mg/kg/day) to rats for 14 days
increased the concentrations of homocysteine in
serum and produced angiotoxic effects similar to
atherosclerosis.29
Conclusions
The combination of methionine and paracetamol in
the same tablet will reduce the incidence and severity
of liver damage from paracetamol overdose and the
subsequent number of deaths provided that methio-
nine is included in all paracetamol preparations
marketed. However, the effect on liver transplantation
would be relatively small. In addition, forcing people
who use paracetamol responsibly to take methionine
when they do not need it raises ethical considerations
and is unacceptable if it poses a health hazard.
Occasional users of the combination are unlikely to be
at any risk, but there are grounds for concern about
those who might consume it regularly over long
periods. Until the long term effects of methionine sup-
plementation can be fully evaluated we believe that
methionine should not be added to every paracetamol
tablet.
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Yes: But perhaps only in developing countries
Edward P Krenzelok
The paracetamol era began in 1886 when it was recog-
nised that acetanilide had analgesic and antipyretic
properties.1 What went unrecognised for years was that
acetanilide’s therapeutic properties were secondary to
paracetamol. The toxicity of acetanilide’s other
metabolite, aniline, was unacceptable, and various
derivatives were synthesised to find a suitable
alternative with analgesic and antipyretic properties.
Phenacetin was soon recognised as a viable alternative,
and paracetamol was first used for medicinal purposes
in 1893.1 However, it did not become popular until
1949.1 In 1995 paracetamol sales in the United States
were roughly $965m (personal communication, IMS
America, Plymouth Meeting, PA 19462-1048).
Poison or remedy?
To paraphrase the Swiss philosopher and physician
Paracelsus: only the dose differentiates a poison from
a remedy. Paracetamol is not an exception to this rule.
At therapeutic doses paracetamol is relatively benign,
but when it is ingested in excessive amounts
endogenous hepatic glutathione is depleted and the
toxic metabolite of paracetamol (N-acetyl-p-
benzoquinoneimine) binds covalently with hepato-
cytes causing cellular death and hepatic necrosis.2 In
1991-5 paracetamol exposure was the most common
incident reported to American poison centres,
accounting for 5.5% of all exposures.3-7 Furthermore,
paracetamol overdose was the leading cause of death
from poisoning, being implicated in 9.9% of such
deaths.
All poisonings are not reported to poison
information centres, and it is estimated that full report-
ing would lead to about 58% more exposures.7
Extrapolating this to the paracetamol data for 1991-5,
the number of poisonings would increase from
518 205 to 1 233 821 and the number of deaths from
355 to 845. An additional 4250 people would suffer life
threatening sequelae. The number of people treated in
a healthcare facility would rise from 130 968 patients
to 311 829. These data represent the United States
only, and the world figures would be staggering.
Paracetamol poisoning is clearly a serious problem—
what are the solutions?
Antidotes
The glutathione surrogate or precursors cysteamine,
methionine and N-acetylcysteine have been used
successfully to treat paracetamol poisoning.2 Currently
in the United States patients are given oral N-acetyl-
cysteine, and other countries use intravenous
N-acetylcysteine (which is not approved in America).2
N-Acetylcysteine is especially effective when used soon
after the overdose.8 Since early intervention is
important the idea of incorporating a prophylactic
antidote, such as methionine, into each paracetamol
tablet was proposed in 1974.9 As a precedent, naloxone
was already incorporated into pentazocine tablets as a
deterrent to abuse.10 However, adding methionine was
dismissed as costly and discriminating against the
majority of people who use paracetamol properly.
Given the large numbers of fatal and life threatening
exposures to paracetamol, is it time to reconsider
incorporation of methionine into every paracetamol
tablet?
Financial justification
The financial implications of hospital treatment, liver
transplantation, and death make adding methionine
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for paracetamol poisoning in America is about $8700/
case (£5400).11 If half of the patients who were treated
in a healthcare facility for paracetamol poisoning were
admitted to hospital over $1.36bn would have been
spent on their care. The number of liver transplants
related to paracetamol poisoning is unknown, but the
costs range from $165 000 to $327 000, excluding the
lifelong expenses for antirejection drugs and other
treatment.12 13 If each lost life was valued at $3.6m,14
paracetamol related deaths would have cost over $3bn.
The expenses incurred for only five years make a
compelling argument for adding methionine to each
paracetamol tablet. But do the financial advantages
outweigh the disadvantages?
Disadvantages
Cost is promoted as the main disincentive. Methionine
costs around £7.50/kg. If 250 mg methionine were
added to each paracetamol tablet the cost of 100
tablets would increase by £1.90. However, methionine
would be considerably less expensive if purchased in
large quantities. Nevertheless, this cost seems a small
price to pay considering the enormous financial
burden associated with overdoses.
There are contentions that methionine may be
mutagenic and carcinogenic. Since some people take
paracetamol daily this could have serious implications.
When sodium chloride and sodium nitrite were
incubated with meat, methionine caused a mutation in
Salmonella typhimurium TA 1535.15 However, this does
not imply that methionine is a universal mutagen.
Methionine has prevented the progression of hepatic
cancer in rats.16 In contrast, methionine deprivation is
thought to have some antitumour activity.17 Excessive
methionine in the diet may induce atherosclerosis in
lagomorphs18 and reduce serum folate concentrations
in humans.19 Clearly, the arguments for and against
adding methionine can be rationalised by using selec-
tive research. There is still much to be learnt about
methionine and its role in many physiological
processes.
Limited possibilities
What are the alternatives to methionine? In developed
countries N-acetylcysteine is abundantly available and
relatively inexpensive,20 although the associated hospi-
tal costs add considerably to the price of treatment. In
these countries it seems better to treat paracetamol
poisoning reactively rather than expose the majority of
people to an unnecessary and more costly substance.
However, my experience in developing nations has
shown that N-acetylcysteine and methionine are not
universally available. If a paracetamol-methionine
combination can be produced economically it may be
ethical to encourage its use in developing nations,
where the introduction of paracetamol often precedes
the availability of N-acetylcysteine and where there are
insufficient financial resources to justify the expense of
treatment.
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How to read a paper
Assessing the methodological quality of published papers
Trisha Greenhalgh
Before changing your practice in the light of a
published research paper, you should decide whether
the methods used were valid. This article considers five
essential questions that should form the basis of your
decision.
Question 1: Was the study original?
Only a tiny proportion of medical research breaks
entirely new ground, and an equally tiny proportion
repeats exactly the steps of previous workers. The vast
majority of research studies will tell us, at best, that a
particular hypothesis is slightly more or less likely to be
correct than it was before we added our piece to the
wider jigsaw. Hence, it may be perfectly valid to do a
study which is, on the face of it, “unoriginal.” Indeed,
the whole science of meta-analysis depends on the lit-
erature containing more than one study that has
addressed a question in much the same way.
The practical question to ask, then, about a new
piece of research is not “Has anyone ever done a simi-
lar study?” but “Does this new research add to the
literature in any way?” For example:
x Is this study bigger, continued for longer, or other-
wise more substantial than the previous one(s)?
x Is the methodology of this study any more rigorous
(in particular, does it address any specific method-
ological criticisms of previous studies)?
x Will the numerical results of this study add
significantly to a meta-analysis of previous studies?
x Is the population that was studied different in any
way (has the study looked at different ages, sex, or
ethnic groups than previous studies)?
x Is the clinical issue addressed of sufficient
importance, and is there sufficient doubt in the minds
of the public or key decision makers, to make new evi-
dence “politically” desirable even when it is not strictly
scientifically necessary?
Question 2: Whom is the study about?
Before assuming that the results of a paper are
applicable to your own practice, ask yourself the
following questions:
x How were the subjects recruited? If you wanted to do a
questionnaire survey of the views of users of the hospi-
tal casualty department, you could recruit respondents
by advertising in the local newspaper. However, this
method would be a good example of recruitment bias
since the sample you obtain would be skewed in favour
of users who were highly motivated and liked to read
newspapers. You would, of course, be better to issue a
questionnaire to every user (or to a 1 in 10 sample of
users) who turned up on a particular day.
x Who was included in the study? Many trials in Britain
and North America routinely exclude patients with
coexisting illness, those who do not speak English,
those taking certain other medication, and those who
are illiterate. This approach may be scientifically
“clean,” but since clinical trial results will be used to
guide practice in relation to wider patient groups it is
not necessarily logical.1 The results of pharmacokinetic
studies of new drugs in 23 year old healthy male
volunteers will clearly not be applicable to the average
elderly woman.
x Who was excluded from the study? For example, a ran-
domised controlled trial may be restricted to patients
with moderate or severe forms of a disease such as
heart failure—a policy which could lead to false
conclusions about the treatment of mild heart failure.
This has important practical implications when clinical
trials performed on hospital outpatients are used to
dictate “best practice” in primary care, where the spec-
trum of disease is generally milder.
x Were the subjects studied in “real life” circumstances? For
example, were they admitted to hospital purely for
observation? Did they receive lengthy and detailed
explanations of the potential benefits of the interven-
tion? Were they given the telephone number of a key
research worker? Did the company that funded the
research provide new equipment which would not be
available to the ordinary clinician? These factors would
not necessarily invalidate the study itself, but they may
cast doubt on the applicability of its findings to your
own practice.
Question 3: Was the design of the study
sensible?
Although the terminology of research trial design can
be forbidding, much of what is grandly termed “critical
appraisal” is plain common sense. I usually start with
two fundamental questions:
x What specific intervention or other manoeuvre was being
considered, and what was it being compared with? It is
tempting to take published statements at face value, but
remember that authors frequently misrepresent (usu-
Summary points
The first essential question to ask about the
methods section of a published paper is: was the
study original?
The second is: whom is the study about?
Thirdly, was the design of the study sensible?
Fourthly, was systematic bias avoided or
minimised?
Finally, was the study large enough, and
continued for long enough, to make the results
credible?
Education and debate
This is the third
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ally subconsciously rather than deliberately) what they
actually did, and they overestimate its originality and
potential importance. The examples in the box use
hypothetical statements, but they are all based on simi-
lar mistakes seen in print.
x What outcome was measured, and how? If you had an
incurable disease for which a pharmaceutical company
claimed to have produced a new wonder drug, you
would measure the efficacy of the drug in terms of
whether it made you live longer (and, perhaps, whether
life was worth living given your condition and any side
effects of the medication). You would not be too inter-
ested in the levels of some obscure enzyme in your
blood which the manufacturer assured you were a reli-
able indicator of your chances of survival. The use of
such surrogate endpoints is discussed in a later article
in this series.2
The measurement of symptomatic effects (such as
pain), functional effects (mobility), psychological effects
(anxiety), or social effects (inconvenience) of an
intervention is fraught with even more problems. You
should always look for evidence in the paper that the
outcome measure has been objectively validated—that
is, that someone has confirmed that the scale of
anxiety, pain, and so on used in this study measures
what it purports to measure, and that changes in this
outcome measure adequately reflect changes in the
status of the patient. Remember that what is important
in the eyes of the doctor may not be valued so highly by
the patient, and vice versa.3
Question 4: Was systematic bias avoided
or minimised?
Systematic bias is defined as anything that erroneously
influences the conclusions about groups and distorts
comparisons.4 Whether the design of a study is a
randomised controlled trial, a non-randomised com-
parative trial, a cohort study, or a case-control study, the
aim should be for the groups being compared to be as
similar as possible except for the particular difference
being examined. They should, as far as possible, receive
the same explanations, have the same contacts with
health professionals, and be assessed the same number
of times by using the same outcome measures.
Different study designs call for different steps to reduce
systematic bias:
Randomised controlled trials
In a randomised controlled trial, systematic bias is (in
theory) avoided by selecting a sample of participants
from a particular population and allocating them ran-
domly to the different groups. Figure 1 summarises









Examples of problematic descriptions in the methods section of a paper
What the authors said
“We measured how often GPs ask
patients whether they smoke.”





“We asked 100 teenagers to
participate in our survey of sexual
attitudes.”
“We randomised patients to either
‘individual care plan’ or ‘usual care’.”
“To assess the value of an educational
leaflet, we gave the intervention group
a leaflet and a telephone helpline
number. Controls received neither.”
“We measured the use of vitamin C in
the prevention of the common cold.”
What they should have said (or should have done)
“We looked in patients’ medical records and counted
how many had had their smoking status recorded.”
“We measured what doctors say they do when faced with
a patient with low back pain.”
“Subjects in the intervention group were asked to apply a
patch containing 15 mg nicotine twice daily; those in the
control group received identical-looking patches.”
“We approached 147 white American teenagers aged
12-18 (85 males) at a summer camp; 100 of them (31
males) agreed to participate.”
“The intervention group were offered an individual care
plan consisting of ...; control patients were offered ....”
If the study is purely to assess the value of the leaflet,
both groups should have been given the helpline
number.
A systematic literature search would have found
numerous previous studies on this subject14
An example of:
Assumption that medical records are
100% accurate.
Assumption that what doctors say
they do reflects what they actually do.
Failure to state dose of drug or
nature of placebo.
Failure to give sufficient information
about subjects. (Note in this example
the figures indicate a recruitment
bias towards females.)
Failure to give sufficient information
about intervention. (Enough
information should be given to allow
the study to be repeated by other
workers.)
Failure to treat groups equally apart
form the specific intervention.
Unoriginal study.
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Non-randomised controlled clinical trials
I recently chaired a seminar in which a multidiscipli-
nary group of students from the medical, nursing,
pharmacy, and allied professions were presenting the
results of several in house research studies. All but one
of the studies presented were of comparative, but non-
randomised, design—that is, one group of patients (say,
hospital outpatients with asthma) had received one
intervention (say, an educational leaflet) while another
group (say, patients attending GP surgeries with
asthma) had received another intervention (say, group
educational sessions). I was surprised how many of the
presenters believed that their study was, or was equiva-
lent to, a randomised controlled trial. In other words,
these commendably enthusiastic and committed young
researchers were blind to the most obvious bias of all:
they were comparing two groups which had inherent,
self selected differences even before the intervention
was applied (as well as having all the additional poten-
tial sources of bias of randomised controlled trials).
As a general rule, if the paper you are looking at is
a non-randomised controlled clinical trial, you must
use your common sense to decide if the baseline differ-
ences between the intervention and control groups are
likely to have been so great as to invalidate any differ-
ences ascribed to the effects of the intervention. This is,
in fact, almost always the case.5 6
Cohort studies
The selection of a comparable control group is one of
the most difficult decisions facing the authors of an
observational (cohort or case-control) study. Few, if any,
cohort studies, for example, succeed in identifying two
groups of subjects who are equal in age, sex mix,
socioeconomic status, presence of coexisting illness,
and so on, with the single difference being their expo-
sure to the agent being studied. In practice, much of
the “controlling” in cohort studies occurs at the analy-
sis stage, where complex statistical adjustment is made
for baseline differences in key variables. Unless this is
done adequately, statistical tests of probability and con-
fidence intervals will be dangerously misleading.7
This problem is illustrated by the various cohort
studies on the risks and benefits of alcohol, which have
consistently found a “J shaped” relation between
alcohol intake and mortality. The best outcome (in
terms of premature death) lies with the cohort who are
moderate drinkers.8 The question of whether “teetotal-
lers” (a group that includes people who have been
ordered to give up alcohol on health grounds, health
faddists, religious fundamentalists, and liars, as well as
those who are in all other respects comparable with the
group of moderate drinkers) have a genuinely
increased risk of heart disease, or whether the J shape
can be explained by confounding factors, has occupied
epidemiologists for years.8
Case-control studies
In case-control studies (in which the experiences of
individuals with and without a particular disease are
analysed retrospectively to identify putative causative
events), the process that is most open to bias is not the
assessment of outcome, but the diagnosis of “caseness”
and the decision as to when the individual became a
case.
A good example of this occurred a few years ago
when a legal action was brought against the manufac-
turers of the whooping cough (pertussis) vaccine,
which was alleged to have caused neurological damage
in a number of infants.9 In the court hearing, the judge
ruled that misclassification of three brain damaged
infants as “cases” rather than controls led to the
overestimation of the harm attributable to whooping
cough vaccine by a factor of three.9
Question 5: Was assessment “blind”?
Even the most rigorous attempt to achieve a compara-
ble control group will be wasted effort if the people
who assess outcome (for example, those who judge
whether someone is still clinically in heart failure, or
who say whether an x ray is “improved” from last time)
know which group the patient they are assessing was
allocated to. If, for example, I knew that a patient had
been randomised to an active drug to lower blood
pressure rather than to a placebo, I might be more
likely to recheck a reading which was surprisingly high.
This is an example of performance bias, which, along
with other pitfalls for the unblinded assessor, is listed in
figure 1.
Question 6: Were preliminary statistical
questions dealt with?
Three important numbers can often be found in the
methods section of a paper: the size of the sample; the
duration of follow up; and the completeness of follow
up.
Sample size
In the words of statistician Douglas Altman, a trial
should be big enough to have a high chance of detect-
ing, as statistically significant, a worthwhile effect if it
exists, and thus to be reasonably sure that no benefit
exists if it is not found in the trial.10 To calculate sample
size, the clinician must decide two things.
The first is what level of difference between the two
groups would constitute a clinically significant effect.
Note that this may not be the same as a statistically sig-

















differences in the care








Fig 1 Sources of bias to check for in a randomised controlled trial
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nificant effect. You could administer a new drug which
lowered blood pressure by around 10 mm Hg, and the
effect would be a significant lowering of the chances of
developing stroke (odds of less than 1 in 20 that the
reduced incidence occurred by chance).11 However, in
some patients, this may correspond to a clinical reduc-
tion in risk of only 1 in 850 patient years12—a difference
which many patients would classify as not worth the
effort of taking the tablets. Secondly, the clinician must
decide the mean and the standard deviation of the
principal outcome variable.
Using a statistical nomogram,10 the authors can
then, before the trial begins, work out how large a sam-
ple they will need in order to have a moderate, high, or
very high chance of detecting a true difference between
the groups—the power of the study. It is common for
studies to stipulate a power of between 80% and 90%.
Underpowered studies are ubiquitous, usually because
the authors found it harder than they anticipated to
recruit their subjects. Such studies typically lead to a
type II or â error—the erroneous conclusion that an
intervention has no effect. (In contrast, the rarer type I
or á error is the conclusion that a difference is signifi-
cant when in fact it is due to sampling error.)
Duration of follow up
Even if the sample size was adequate, a study must con-
tinue long enough for the effect of the intervention to
be reflected in the outcome variable. A study looking at
the effect of a new painkiller on the degree of postop-
erative pain may only need a follow up period of 48
hours. On the other hand, in a study of the effect of
nutritional supplementation in the preschool years on
final adult height, follow up should be measured in
decades.
Completeness of follow up
Subjects who withdraw from (“drop out of”) research
studies are less likely to have taken their tablets as
directed, more likely to have missed their interim
checkups, and more likely to have experienced side
effects when taking medication, than those who do not
withdraw.13 The reasons why patients withdraw from
clinical trials include the following:
x Incorrect entry of patient into trial (that is,
researcher discovers during the trial that the patient
should not have been randomised in the first place
because he or she did not fulfil the entry criteria);
x Suspected adverse reaction to the trial drug. Note
that the “adverse reaction” rate in the intervention
group should always be compared with that in patients
given placebo. Inert tablets bring people out in a rash
surprisingly frequently;
x Loss of patient motivation;
x Withdrawal by clinician for clinical reasons (such as
concurrent illness or pregnancy);
x Loss to follow up (patient moves away, etc);
x Death.
Simply ignoring everyone who has withdrawn from
a clinical trial will bias the results, usually in favour of
the intervention. It is, therefore, standard practice to
analyse the results of comparative studies on an inten-
tion to treat basis.14 This means that all data on patients
originally allocated to the intervention arm of the
study—including those who withdrew before the trial
finished, those who did not take their tablets, and even
those who subsequently received the control interven-
tion for whatever reason—should be analysed along
with data on the patients who followed the protocol
throughout. Conversely, withdrawals from the placebo
arm of the study should be analysed with those who
faithfully took their placebo.
In a few situations, intention to treat analysis is not
used. The most common is the efficacy analysis, which
is to explain the effects of the intervention itself, and is
therefore of the treatment actually received. But even if
the subjects in an efficacy analysis are part of a
randomised controlled trial, for the purposes of the
analysis they effectively constitute a cohort study.
Thanks to Dr Sarah Walters and Dr Jonathan Elford for advice
on this article.
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